2026-04-13T00:50:22Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/127132025-10-24T10:40:53Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Schoot, Reineke Anna
author
Taselaar, Pieter Michael
author
Kolb, Frederic
author
ter Horst, Simone
author
Hladun Alvaro, Raquel
author
Scarzello, Giovanni
author
Coppadoro, Beatrice
2025-10-24T10:40:53Z
2025-10-24T10:40:53Z
2025-03-07T11:39:04Z2025-03-07T11:39:04Z2025-03
http://hdl.handle.net/11351/12713
Head and neck; Prognostic risk factors; RhabdomyosarcomaCabeza y cuello; Factores de riesgo pronóstico; RabdomiosarcomaCap i coll; Factors de risc pronòstic; RabdomiosarcomaBackground
Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension.
Methods
Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment.
Results
Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%–65%), 5-year overall survival was 65% (95% CI 60%–70%).
Conclusions
The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors.
Trial Registration
EudraCT number 2005-000217-35This work was supported by Royal Marsden Cancer Charity, Alice's Arc, children's cancer charity, and NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research.
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Infants
Tumors de parts toves - Tractament
Músculs - Càncer - Prognosi
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Muscle Tissue::Myosarcoma::Rhabdomyosarcoma
Other subheadings::Other subheadings::/therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Meningeal Neoplasms
Other subheadings::Other subheadings::/therapy
NAMED GROUPS::Persons::Age Groups::Child
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::miosarcoma::rabdomiosarcoma
Otros calificadores::Otros calificadores::/terapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias meníngeas
Otros calificadores::Otros calificadores::/terapia
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion